ALINS Stock Overview
Intrasense SA designs and develops software solution for advanced visualization and analysis of multimodality medical images under the Myrian name worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Intrasense S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.28 |
| 52 Week High | €0.52 |
| 52 Week Low | €0.20 |
| Beta | -0.84 |
| 11 Month Change | 1.09% |
| 3 Month Change | -1.06% |
| 1 Year Change | -31.78% |
| 33 Year Change | -55.36% |
| 5 Year Change | 3.52% |
| Change since IPO | -96.13% |
Recent News & Updates
Shareholder Returns
| ALINS | FR Healthcare Services | FR Market | |
|---|---|---|---|
| 7D | 1.1% | -2.7% | -0.3% |
| 1Y | -31.8% | -12.0% | -3.5% |
Return vs Industry: ALINS underperformed the French Healthcare Services industry which returned -11.6% over the past year.
Return vs Market: ALINS underperformed the French Market which returned -2.5% over the past year.
Price Volatility
| ALINS volatility | |
|---|---|
| ALINS Average Weekly Movement | 13.3% |
| Healthcare Services Industry Average Movement | 5.9% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALINS's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALINS's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 74 | Alexandre Salvador | www.intrasense.fr |
Intrasense SA designs and develops software solution for advanced visualization and analysis of multimodality medical images under the Myrian name worldwide. The company offers Myrian Imaging Layer, a multimodal visualization software platform suite for health industrials; Myrian Studio, a solution for the development of medical imaging applications for innovators, industrial clients, spin-offs, and research labs; and Myrian technologies to develop biomarkers and artificial intelligence solutions. It also provides Myrian Clinical Apps, a portfolio of clinical applications for advanced post-processing, which include Myrian XP-Breast; Myrian XP-Prostate; Myrian XP-Liver; Myrian XP-Mammo; Myrian XP-Lung; Myrian XP-Colon; Myrian XL-Onco, a lesion tracking solutions; Myrian XP-Vessel; Myrian XP-Cardiac; solution for pathology or organ; and various tools for the analysis of MRI, CT, conventional, radiology, and nuclear imaging exams.
Intrasense S.A. Fundamentals Summary
| ALINS fundamental statistics | |
|---|---|
| Market cap | €14.67m |
| Earnings (TTM) | -€3.89m |
| Revenue (TTM) | €2.33m |
6.3x
P/S Ratio-3.8x
P/E RatioIs ALINS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALINS income statement (TTM) | |
|---|---|
| Revenue | €2.33m |
| Cost of Revenue | €3.78m |
| Gross Profit | -€1.45m |
| Other Expenses | €2.44m |
| Earnings | -€3.89m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.074 |
| Gross Margin | -62.06% |
| Net Profit Margin | -166.91% |
| Debt/Equity Ratio | 17.1% |
How did ALINS perform over the long term?
See historical performance and comparison